MEI Pharma (MEIP) Stock: Here’s What You Need To Know

MEI Pharma Inc. (NASDAQ:MEIP) On Monday, MEI pharma released results of its phase 2 clinical trial in elderly patients with Acute Myeloid Leukemia – AML. These results were presented at a prestigious medical conference known as the American Society of Hematology or ASH. The results themselves were outstanding, but the stock didn’t budge at all. … Read more

Acadia Pharmaceuticals (ACAD) Stock: Here’s What You Need To Know!

Acadia Pharmaceuticals (NASDAQ:ACAD) On Monday, Acadia Pharmaceuticals announced that it had initiated a phase 2 trial in patients with Alzheimer’s Disease Agitation. Once again ACAD will use its drug Pimavanserin to see if the drug will work in this targeted indication. The company has already received FDA approval for Pimavanserin in Parkinson’s Disease Psychosis. Now … Read more

Juno Therapeutics (JUNO) Stock: Here’s What You Need To Know

Juno Therapeutics (NASDAQ: JUNO) On July 12, 2016 it was announced that the FDA had released the clinical hold for the company’s lead drug candidate  JCAR015. A few weeks prior the FDA had put Juno’s trial, known as ROCKET, on a clinical hold because there were two patient deaths in the trial. The company proclaimed … Read more

Biotech Stock News (INO) (AZN) (IMUC) (AAVL) (REGN)

Inovio Pharmaceuticals (NASDAQ:INO) On August 10, 2015 shares of Inovio were up about 25% after the company announced a partnership deal with a big pharmaceutical company known as AstraZeneca (NYSE:AZN). Although one key thing to note here is that this deal is being established with MedImmune specifically, but it is the research and development arm for … Read more

Biotech News- 2/9/15 to 2/13/15

Achillion Pharmaceuticals (ACHN) Shares of Achillion gained 7% on 2/9/15 last week when it had announced that it had achieved a 100% SVR12 in a phase 2 trial treating patients with the genotype 1 version of the Hepatitis C virus — HCV. The trial tested for the primary objective of patients being able to achieve a … Read more